Cargando…
An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major
BACKGROUND: Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or t...
Autores principales: | Iniguez, Eva, Schocker, Nathaniel S., Subramaniam, Krishanthi, Portillo, Susana, Montoya, Alba L., Al-Salem, Waleed S., Torres, Caresse L., Rodriguez, Felipe, Moreira, Otacilio C., Acosta-Serrano, Alvaro, Michael, Katja, Almeida, Igor C., Maldonado, Rosa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673233/ https://www.ncbi.nlm.nih.gov/pubmed/29069089 http://dx.doi.org/10.1371/journal.pntd.0006039 |
Ejemplares similares
-
A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease
por: Montoya, Alba L., et al.
Publicado: (2022) -
Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins
por: Viana, Sayonara M., et al.
Publicado: (2022) -
Cutaneous Leishmaniasis and Conflict in Syria
por: Al-Salem, Waleed S., et al.
Publicado: (2016) -
A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease
por: Portillo, Susana, et al.
Publicado: (2019) -
Specific Recognition of β-Galactofuranose-Containing Glycans of Synthetic Neoglycoproteins by Sera of Chronic Chagas Disease Patients
por: Montoya, Alba L., et al.
Publicado: (2022)